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Previewsgenetically engineered mice lacking UT-
A1/UT-A3, UT-A2, UT-B1, or UT-A2 and
UT-B1 (reviewed in Klein, et al., 2011,
2012). Thus, an inhibitor of any of these
urea transporters may result in a diuresis.
Urea plays a critical role in the urinary
concentrating mechanism and in the
maintenance of water balance (reviewed
in Sands and Layton, 2013 and Sands,
et al., 2011). Protein-deprivation or a
low-protein diet reduces maximal urine
concentrating ability, and hence the abil-
ity to conserve water, and is restored by
urea infusion. As mentioned above, mice
with genetic knock-out of both IMCD
urea transporters, UT-A1 and UT-A3,
have a urine concentrating defect. The
polyuria in these mice results from the
absence of urea transport in their IMCD
(Fenton, et al., 2004).
Here, Esteva-Font et al. (2013) report a
selective inhibitor of the UT-A1 urea trans-
porter as well as a UT-A1/UT-B1 nonse-
lective inhibitor. Whereas an inhibitor of
UT-B1 that is metabolically stable and
works at nanomolar potency has been re-
ported previously (Anderson, et al., 2012;
Yao, et al., 2012), this study is, to the
best of my knowledge, the first to report
a UT-A1 selective inhibitor. Further devel-
opment and in vivo testing of this intriguing1202 Chemistry & Biology 20, October 24, 20compound would be quite exciting.
Although future studies in animals will be
needed to assess the ability of UT-A1 in-
hibitors to induce and sustain a diuresis,
it seems likely that UT-A1 inhibitors will
be effective. A UT-A1 inhibitor is particu-
larly attractive as a drug target, because
having a diuretic that works by inhibiting
urea transport in the last nephron segment
offers the exciting possibility that it will
have less undesirable side effects on elec-
trolytes than the conventional diuretics
that inhibit sodium transport in the thick
ascending limb or distal convoluted tu-
bule. In addition, a UT-A1 inhibitor would
have a different mechanism of action
from other diuretics and would be the first
diuretic to act in the IMCD. This opens the
possibility for combination therapy with
other diuretics, in addition tomonotherapy
with a UT-A1 inhibitor.
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In this issue of Chemistry & Biology, Jahnsen and colleagues describe a multimodal mechanism of action of
an unusual peptide-peptoid hybrid with broad-spectrum antibacterial activity. They demonstrate that the
molecule has effects on many aspects of bacterial metabolism and also modulates host immune responses.Pathogenic, multi-drug-resistant bacterial
strains are becoming increasingly com-
mon. Thus, development of new antibac-
terial compounds is of great interest. One
line of research that has achieved much
attention is host defense peptides. Thesepeptides function, at least in part, by in-
serting into the membranes of bacteria
and depolarizing them. Treatment of bac-
teria with helical defense peptides such
as mellittin results in bacterial cell lysis.
Unfortunately, there has been limited suc-cess in bringing these peptides into the
clinic. Toxicity is an issue, because a
huge selectivity for insertion into bacterial
membranes rather than the membranes
of eukaryotic cells is required, as is the sta-
bility of peptides in serum.
Chemistry & Biology
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Jahnsen et al. (2013) analyze the mode
of action of a host defense peptide called
HDP4 (Jahnsen et al., 2012). HDP4 is a
16-mer that has an unusual structure of
alternating lysine and N-benzylglycine
residues. The N-substitution blocks enzy-
matic degradation of HDP4. Moreover,
HDP4 exhibits very low toxicity in
mammalian cells (Jahnsen et al., 2012),
making it an interesting candidate for
further study and development.
Jahnsen et al. (2013) show that HDP4 is
active against a broad spectrum of Gram-
negative bacteria. HDP4 is shown to bind
to bacterial membranes and alter their
structure, but quantitative analysis of
these effects with respect to the MIC
reveal that this cannot be the sole mode
of killing. Indeed, the authors create a flu-
orescently labeled version of the peptideand show that it is broadly distributed in
the bacterial cell, not simply localized to
the membrane. It appears to bind to bac-
terial DNA and probably a variety of other
macromolecules in the cells. Treatment of
bacteria with HDP4 inhibits the formation
of biofilms. In addition, the peptide has
significant effects on host cell responses
to infection as well. It stimulates the
release of chemokines such as IL-8, but
suppresses LPS-induced inflammatory
responses, such as the release of the
proinflammatory TNF-a. As one might
expect from this multimodal killing mech-
anism, the authors demonstrate that bac-
teria are unable to develop resistance to
HDP4 with anywhere near the efficiency
observed for drugs with a single enzy-
matic target.
It is quite remarkable that such a simple
molecule, containing only two differentChemistry & Biology 20, October 24, 2013 ªresidues, is able to exert somany different
effects. Clearly, much work remains to be
done in order to understand these events
in more detail. Nonetheless, from a prac-
tical point of view, the data are intriguing.
The authors argue that this interesting
combination of a simple structure, proteo-
lytic stability, very low mammalian cell
toxicity, and multimodal mechanism of
action merit further investigation of
HDP4 or derivatives as potential clinical
candidates.REFERENCES
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Fluorescent proteins are used as noninvasive tags for protein trafficking, structure, and action. In this issue of
Chemistry & Biology, Hoi and colleagues present a new optimized zFP538 yellow fluorescent protein called
mPapaya1 that is bright, monomeric, and an excellent fusion partner for cellular proteins.Imaging proteins fused to fluorescent pro-
teins (FPs) is a cornerstone of modern
cellular biology and biophysics (Crivat
and Taraska, 2012). This method allows
proteins to be observed and studied in
living cells, tissues, and organisms. FPs
that are bright, structurally stable, and
monomeric are generally the best
choice to noninvasively tag a protein part-
ner for live cell imaging. A tremendous
amount of work over the last 15 years
through protein engineering, directed
evolution, and the discovery new FPs
from different organisms has led to the
development of many excellent FPs
that span the visible spectrum (Crivat
and Taraska, 2012).Some notable holes, however, in the
FP toolset have been difficult to fill. For
example, no stable bright monomeric
FPs with emissions sitting in the yellow
region between 530 nm and 560 nm
have been found (Davidson and Camp-
bell, 2009). This spectral gap rests
between the most red-shifted Aequorea
victoria GFP mutants and the most
blue-shifted Discosoma red FP (dsRed)
variants. Red-shifted GFP variants such
as mVenus and mCitrine have the closest
emission peaks at 528 and 529 nm,
respectively. These proteins have a
tyrosine at position 203 that interacts
via p-p stacking with the Tyr66-derived
phenol ring of the chromophore. Thep-electron orbital of Tyr203 is thought
to affect the electronic transition of the
chromophore to red-shift the emission
wavelength (Davidson and Campbell,
2009). Along with other folding and
stabilization mutations, these proteins
have become useful bright yellow FPs
(YFPs). Their utility as fluorescence reso-
nance energy transfer (FRET) acceptors,
however, has been controversial. Some
reports have shown that photo-bleaching
of YFP-like proteins can generate a cyan
FP-like species (Kirber et al., 2007; Val-
entin et al., 2005). This spurious color
switching could seriously skew quan-
titative FRET measurements. Others,
however, have failed to show this2013 Elsevier Ltd All rights reserved 1203
